Please use this identifier to cite or link to this item:
Title: Oral human β-defensin 2 in HIV-infected subjects with long-term use of antiretroviral therapy
Authors: Nittayananta W.
Kemapunmanus M.
Amornthatree K.
Talungchit S.
Sriplung H.
Keywords: beta defensin 2
RNA directed DNA polymerase inhibitor
cheek mucosa
controlled study
cross-sectional study
enzyme linked immunosorbent assay
highly active antiretroviral therapy
Human immunodeficiency virus infected patient
Human immunodeficiency virus infection
human tissue
major clinical study
mouth examination
priority journal
protein expression
real time polymerase chain reaction
saliva analysis
Analysis of Variance
Anti-HIV Agents
Antimicrobial Cationic Peptides
Case-Control Studies
CD4 Lymphocyte Count
Cross-Sectional Studies
HIV Infections
Immunity, Innate
Middle Aged
Mouth Mucosa
Regression Analysis
Reverse Transcriptase Inhibitors
Reverse Transcriptase Polymerase Chain Reaction
Salivary Proteins and Peptides
Statistics, Nonparametric
Viral Load
Young Adult
Issue Date: 2013
Abstract: Background: The objectives of this study were to determine (i) oral hBD2 expression in HIV-infected subjects compared with non-HIV controls, (ii) the expression of oral hBD2 in HIV-infected subjects with antiretroviral therapy (ART) compared with those without ART, and (iii) factors associated with the expression of oral hBD2. Methods: Oral examination and punched biopsy on buccal mucosa were performed in HIV-infected subjects with and without ART, and non-HIV individuals. The expression of hBD2 mRNA was determined by quantitative real-time PCR. Saliva samples of both un-stimulated and stimulated saliva were collected and analyzed for hBD2 levels using ELISA. Student's t-test and nonparametric multi-way ANOVA test were used for comparison of measurements between or among groups. Results: One hundred and fifty-seven HIV-infected subjects were enrolled: 99 on ART (age range, 23-57years; mean 39years), 58 not on ART (age range, 20-59years; mean 34years), and 50 non-HIV controls (age range, 19-59years; mean 36years). The most common ART regimen was two nucleoside reverse transcriptase inhibitors+one non-nucleoside reverse transcriptase inhibitor. Salivary levels of hBD2 were significantly increased in HIV infection (P<0.001). The levels of hBD2 in stimulated saliva were also found to be significantly different between HIV-infected subjects who were and were not on ART (P<0.001). No significant difference was observed with the expression of hBD2 mRNA. Conclusion: Oral innate immunity is affected by HIV infection and use of ART. Salivary hBD2 levels may be the useful biomarkers to monitor those on long-term ART who are at risk of developing oral infections and malignant transformation. © 2012 John Wiley & Sons A/S.
ISSN: 9042512
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.

Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.